Ernexa Therapeutics Inc.

ERNA Healthcare Biotechnology

Ernexa Therapeutics Inc.’s revenue for fiscal 2024 (year ended December 2024) was $582,000.00, up 755.9% from fiscal 2023. In the quarter to June 2026, revenue fell 94.1%, EPS grew 77.7% and free cash flow fell 64.1%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.

2.09 0.08 −3.69%
Market cap
$3.5M
P/E
0.0×
Fwd P/E
−0.5×
Dividend yield
—
F-score
n/a
Altman Z
−70.69
Beneish M
−24.48
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

— — — —
EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
1.58 1.01 2.89 2.01
Net Debt/EBITDA
1.58 0.93 2.65 1.24
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(3.93) (4.61) (2.86) (3.51)
Book value per Share
10.85 9.52 8.66 2.71
Free Cash Flow
(1.29) (1.16) (2.27) (4.15)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates